Quick Search:

1540 yoga for older adults with multimorbidity: randomised controlled trial with embedded economic and process evaluations

Tew, Garry ORCID: https://orcid.org/0000-0002-8610-0613, Wiley, L, Ward, L, Hugill-Jones, J, Maturana, C, Fairhurst, C, Bell, K, Bissell, L, Booth, A, Howsam, J, Mount, V, Rapley, T, Ronaldson, S, Rose, F, Torgerson, D J, Yates, D and Hewitt, C (2023) 1540 yoga for older adults with multimorbidity: randomised controlled trial with embedded economic and process evaluations. Age and Ageing, 52 (Supple).

Full text not available from this repository.


Older adults with multimorbidity can experience poor health-related quality of life (HRQOL). Yoga has the potential to improve HRQOL. The British Wheel of Yoga’s Gentle Years Yoga© (GYY) programme was developed for older adults with chronic conditions. We investigated the effectiveness and cost-effectiveness of the GYY programme in older adults with multimorbidity.

This was a multi-site, individually randomised, open, superiority trial with embedded economic and process evaluations. Community-dwelling adults aged ≥65 years with ≥2 chronic conditions were recruited from general practices. All participants continued with usual care. Intervention participants were offered a 12-week GYY programme, which changed from face-to-face to online delivery during COVID-19. Most outcomes were participant reported. The primary outcome and endpoint was health-related utility measured using the EQ-5D-5L over 12 months. Secondary outcomes were HRQOL, depression, anxiety, loneliness, falls, adverse events and healthcare resource use.

The mean age of the 454 participants was 73.5 years, 60.6% were female, and the median number of conditions was three. The primary analysis (n=422) showed no statistically or clinically significant difference in the EQ-5D-5L utility score over 12 months (adjusted mean difference of 0.020 favouring intervention; 95% CI -0.006 to 0.045, p=0.14). No statistically significant differences were observed in key secondary outcomes. No serious, related adverse events were reported. The intervention cost £80.85 more per participant (95% CI £76.73 to £84.97) than usual care, generated an additional 0.0178 quality-adjusted life years (QALYs) per participant (95% CI 0.0175 to 0.0180), and had a 79% probability of being cost-effective at a willingness-to-pay threshold of £20,000 per QALY gained.

The GYY programme showed no statistically significant benefits in terms of HRQOL, mental health, loneliness or falls. However, the intervention was safe, acceptable to most participants, and highly valued by some. The economic evaluation suggests that the intervention could be cost-effective.

Item Type: Article
Status: Published
DOI: https://doi.org/10.1093/ageing/afad104.077
School/Department: School of Science, Technology and Health
URI: https://ray.yorksj.ac.uk/id/eprint/8307

University Staff: Request a correction | RaY Editors: Update this record